In this Q&A, Rob Stransky of NiceRx explains how to screen patients for gray-market retatrutide use and why cost drives demand for unregulated peptides.
Rob Stransky
Advertisement
Rob Stransky is the founder of NiceRx.
Articles by Rob Stransky
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Survodutide Meets CV Safety End Point in SYNCHRONIZE-CVOT
2
FDA Approves First Dual-Targeted Therapy for Advanced HNSCC
3
Pharmacy, Claims Data Show High Resmetirom Persistence in MASH
4
Phase 3 Data Back ALP Normalization as Treatment Goal in PBC
5